Xeris Biopharma (NASDAQ:XERS) Insider Sells 25,000 Shares of Stock

Key Points

• Insider sale: Kevin McCulloch sold 25,000 Xeris Biopharma shares for $250,000 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 1.53% to 1.61 million shares.
• Stock performance and earnings: XERS traded near $9.98, up from a 52-week low of $5.25, but the company reported a quarterly EPS loss of $0.18 versus the $0.01 consensus estimate despite revenue exceeding expectations.
• Analyst outlook: Analyst views remain mixed, with four Buy, two Hold, and one Sell rating; the consensus price target is $12.80, while recent targets range from $12 to $16.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin McCulloch sold 25,000 shares of the business's stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $10.00, for a total value of $250,000.00. Following the transaction, the insider directly owned 1,614,208 shares of the company's stock, valued at $16,142,080. This represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total value of $127,350.00.
• On Monday, August 3rd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.02, for a total value of $120,300.00.
• On Wednesday, July 1st, Kevin McCulloch sold 90,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.03, for a total value of $722,700.00.

Xeris Biopharma Stock Performance

Shares of XERS stock traded up $0.15 during trading hours on Tuesday, reaching $9.98. 19,292,234 shares of the company's stock were exchanged, compared to its average volume of 1,973,664. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $11.33. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The stock has a market capitalization of $1.82 billion, a P/E ratio of -90.73 and a beta of 0.70. The business has a fifty day moving average price of $8.38 and a 200-day moving average price of $7.20.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of XERS. Integrated Wealth Concepts LLC acquired a new position in shares of Xeris Biopharma during the second quarter valued at $74,000. Allworth Financial LP increased its position in Xeris Biopharma by 86.4% in the second quarter. Allworth Financial LP now owns 4,315 shares of the company's stock worth $34,000 after purchasing an additional 2,000 shares during the period. Allianz Asset Management GmbH acquired a new stake in Xeris Biopharma in the second quarter worth about $314,000. Corient Private Wealth LP bought a new stake in Xeris Biopharma during the 2nd quarter worth about $1,458,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Xeris Biopharma during the 2nd quarter worth about $89,000. 42.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Wall Street Zen upgraded Xeris Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, September 19th. Leerink Partners boosted their price objective on Xeris Biopharma from $12.00 to $16.00 and gave the stock an "outperform" rating in a research note on Thursday, September 10th. Finally, Barclays lifted their price target on Xeris Biopharma from $9.00 to $12.00 and gave the company an "overweight" rating in a report on Thursday, August 20th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $12.80.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc NASDAQ: XERS is a specialty pharmaceutical company focused on developing and commercializing therapies using proprietary formulation and drug-delivery technologies. Its platforms, including XeriSol and XeriJect, are designed to enable liquid or ready-to-use formulations of medicines that may otherwise require refrigeration, reconstitution, or administration by a healthcare professional.

The company's commercial products include Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia; Keveyis (dichlorphenamide), an oral therapy for primary periodic paralysis; and Recorlev (levoketoconazole), an oral treatment for endogenous hypercortisolemia in adults with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.